Fibromyalgia
Chapter notes (PDF)PDFChronic widespread pain syndrome characterised by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive dysfunction ('fibro fog') in the absence of an identifiable structural or inflammatory cause. Affects 2-4% of the UK population, predominantly women.
Key Facts
- Fibromyalgia is a central sensitisation syndrome characterised by widespread pain, fatigue, sleep disturbance, and cognitive dysfunction ('fibro fog')
- Affects 2-4% of the UK population; F:M 6-9:1; peak onset 30-50 years
- Diagnosis is clinical: ACR 2010/2016 criteria use Widespread Pain Index (WPI) and Symptom Severity Scale (SSS); no diagnostic blood test or imaging
- All investigations are normal: FBC, ESR/CRP, TFTs, CK – performed to exclude other diagnoses
- NICE recommends: graded exercise (most effective intervention), CBT, amitriptyline 10-25mg nocte or duloxetine 30-60mg or pregabalin 150-300mg
- NOT recommended: opioids (no evidence of benefit, significant harm), routine imaging, repeated investigations
- Commonly coexists with: IBS, chronic fatigue syndrome, migraine, TMJ dysfunction, depression, anxiety
- Pathophysiology: central sensitisation – augmented pain processing in CNS, reduced descending inhibitory pain modulation
Overview
Key Facts
Fibromyalgia is a real condition with demonstrable neurobiological abnormalities in pain processing. It is not 'all in the mind' but requires a biopsychosocial management approach.
Epidemiology
- UK prevalence: 2-4%
- F:M 6-9:1
- Peak onset: 30-50 years
- Common in rheumatology clinics (15-20% of referrals)
Pathophysiology
- Central sensitisation: augmented pain processing in spinal cord and brain
- Reduced descending inhibitory pain modulation (serotonin, noradrenaline pathways)
- Elevated substance P in cerebrospinal fluid
- Abnormal functional MRI: increased activation of pain-processing regions
- Sleep architecture disruption: alpha-wave intrusion into stage 4 (deep) sleep
- Neuroendocrine: HPA axis dysregulation, low growth hormone
- Risk factors: genetic predisposition, physical/emotional trauma, chronic stress, other chronic pain conditions
Clinical Presentation
Core Features
- Widespread pain: both sides of body, above and below waist, axial involvement; described as aching, burning, shooting
- Fatigue: often profound; not relieved by rest
- Sleep disturbance: unrefreshing sleep, difficulty falling/staying asleep
- Cognitive dysfunction ('fibro fog'): difficulty concentrating, poor memory, word-finding difficulty
Associated Symptoms
- Headaches (tension-type, migraine)
- IBS (abdominal pain, bloating, altered bowel habit)
- TMJ pain
- Paraesthesiae
- Morning stiffness (not prolonged as in inflammatory arthritis)
- Dizziness
- Depression and anxiety (>50%)
- Sensitivity to noise, light, temperature
Examination
- No objective joint swelling or inflammation
- Widespread tenderness to palpation
- Normal neurological examination
- Normal joint examination (may have some tender points)
Red Flags (Suggesting Alternative Diagnosis)
- True joint swelling → inflammatory arthritis
- Significant weight loss → malignancy, endocrine disease
- True muscle weakness → myopathy
- Abnormal blood tests → investigate further
- Progressive neurological signs → MS, neuropathy
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| PMR | Age >50, shoulder/hip girdle, raised ESR/CRP | ESR, CRP |
| Hypothyroidism | Fatigue, weight gain, constipation | TFTs |
| Vitamin D deficiency | Widespread pain, fatigue | 25-OH-vitamin D |
| RA | Joint swelling, RF/CCP positive | RF, anti-CCP, ESR |
| SLE | Multi-system, ANA positive | ANA, dsDNA |
| Depression | Low mood, anhedonia | PHQ-9 |
| Chronic fatigue syndrome | Fatigue predominant, PEM | Clinical |
Diagnosis / Investigation
Investigations to Exclude Other Diagnoses
- FBC: normal (exclude anaemia)
- ESR/CRP: normal (exclude inflammatory conditions)
- TFTs: normal (exclude hypothyroidism)
- CK: normal (exclude myopathy)
- Calcium, vitamin D: exclude deficiency
- HbA1c: exclude diabetes
- Coeliac screen (tTG): if GI symptoms
NOT Required
- Routine X-rays or MRI (unless specific indication)
- ANA, RF (unless clinical features of autoimmune disease)
- Repeated investigations → reinforce illness behaviour
Diagnosis
- ACR 2010/2016 criteria: WPI ≥7 + SSS ≥5 (or WPI 4-6 + SSS ≥9); symptoms present ≥3 months; no other explanation
- Clinical diagnosis: widespread pain + fatigue + sleep disturbance + cognitive symptoms + normal investigations
Management
Non-pharmacological (Most Important)
- Graded aerobic exercise: most effective intervention; start low, increase gradually (swimming, walking, cycling)
- CBT: addresses catastrophising, pacing, coping strategies
- Patient education: understanding the condition, self-management (Versus Arthritis resources)
- Sleep hygiene: regular sleep schedule, avoid caffeine/screens before bed
- Mindfulness/relaxation: stress reduction
- Hydrotherapy: warm water exercise
Pharmacological
- Amitriptyline 10-25mg nocte: first-line; improves pain, sleep, and mood (NICE)
- Duloxetine 30-60mg OD: SNRI; for pain and comorbid depression/anxiety
- Pregabalin 150-300mg/day: for pain; α2δ ligand (gabapentinoid)
- Gabapentin: alternative to pregabalin
- Cyclobenzaprine: muscle relaxant (less used in UK)
- Tramadol: may be used cautiously for severe pain (some guidelines); avoid long-term
NOT Recommended
- Strong opioids (morphine, fentanyl): no evidence of benefit; significant harm (dependence, hyperalgesia)
- NSAIDs: minimal benefit in fibromyalgia (no peripheral inflammation)
- Corticosteroids: no role
- Benzodiazepines: avoid (dependence, worsens fatigue)
Multidisciplinary Approach
- Pain management programme: most effective model
- Physiotherapy, psychology, occupational therapy
- Self-management programmes
Referral Criteria
- Diagnostic uncertainty → rheumatology (one-off assessment)
- Severe, refractory symptoms → pain management team
- Significant psychological comorbidity → psychology/psychiatry
Prognosis
- Chronic condition with fluctuating symptoms
- No excess mortality associated with fibromyalgia itself
- 50-60% of patients report significant improvement with multidisciplinary management
- Exercise: most consistent evidence for sustained benefit
- Functional outcomes: variable; many patients maintain employment and function
- Factors associated with poorer outcomes: high catastrophising, low self-efficacy, comorbid mental health conditions, opioid use
- Spontaneous remission: uncommon but possible (~25% over 10 years)
Other Relevant Information
ACR 2010 Fibromyalgia Criteria
Widespread Pain Index (WPI): Count of 19 body areas with pain (range 0-19) Symptom Severity Scale (SSS): Fatigue + unrefreshing sleep + cognitive symptoms (0-3 each) + headaches, abdominal pain, depression (0-3)
Fibromyalgia if: (WPI ≥7 AND SSS ≥5) OR (WPI 4-6 AND SSS ≥9); symptoms ≥3 months; no other disorder explaining pain
Pharmacological Comparison
| Drug | Mechanism | Key Benefits | Side Effects |
|---|---|---|---|
| Amitriptyline | TCA | Pain, sleep | Dry mouth, weight gain, sedation |
| Duloxetine | SNRI | Pain, mood | Nausea, dizziness |
| Pregabalin | α2δ ligand | Pain, anxiety | Weight gain, sedation, dizziness |